| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study
|
Dressen, Amy
|
|
2018
|
6 |
8 |
p. 603-614
|
artikel
|
| 2 |
Atezolizumab in patients with metastatic NSCLC
|
Williamson, Jack
|
|
2018
|
6 |
8 |
p. 584
|
artikel
|
| 3 |
Benefits of set length antibiotic treatment for pulmonary exacerbations
|
Goss, Christopher H
|
|
2018
|
6 |
8 |
p. 575-577
|
artikel
|
| 4 |
Black soot
|
Kalu, Bernard
|
|
2018
|
6 |
8 |
p. 587
|
artikel
|
| 5 |
Co-opting of ClinicalTrials.gov by patient-funded studies
|
Wagner, Darcy E
|
|
2018
|
6 |
8 |
p. 579-581
|
artikel
|
| 6 |
COPD awareness and treatment in China
|
Xu, Guodong
|
|
2018
|
6 |
8 |
p. e38
|
artikel
|
| 7 |
COPD ground zero: small airways rather than alveoli as the initial site of injury
|
Russell, Derek W
|
|
2018
|
6 |
8 |
p. 568-569
|
artikel
|
| 8 |
Dangers of COPD and asthma under-recognised among Hajj pilgrims
|
Liew, Su May
|
|
2018
|
6 |
8 |
p. 590
|
artikel
|
| 9 |
Disadvantages of set length antibiotic treatment for pulmonary exacerbation
|
Stephen, Michael J
|
|
2018
|
6 |
8 |
p. 573-575
|
artikel
|
| 10 |
Gazing into the crystal ball: can treatment response be predicted in IPF?
|
Kreuter, Michael
|
|
2018
|
6 |
8 |
p. 570-572
|
artikel
|
| 11 |
Guideline provides new diagnostic insights for PCD
|
The Lancet Respiratory Medicine,
|
|
2018
|
6 |
8 |
p. 567
|
artikel
|
| 12 |
Mica pneumoconiosis: a neglected occupational lung disease
|
Moitra, Subhabrata
|
|
2018
|
6 |
8 |
p. e39
|
artikel
|
| 13 |
Occupational dust and cigarette smoke exposure might link rheumatoid arthritis to COPD
|
Murphy, Dan
|
|
2018
|
6 |
8 |
p. e36
|
artikel
|
| 14 |
Past exposures leave a legacy of pulmonary disease in South Korea
|
Furlow, Bryant
|
|
2018
|
6 |
8 |
p. 585-586
|
artikel
|
| 15 |
Placebo-controlled trials of vitamin D and asthma
|
Celedón, Juan C
|
|
2018
|
6 |
8 |
p. e42
|
artikel
|
| 16 |
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials
|
Neighbors, Margaret
|
|
2018
|
6 |
8 |
p. 615-626
|
artikel
|
| 17 |
Pulmonary hypertension: the unaddressed global health burden
|
Rich, Stuart
|
|
2018
|
6 |
8 |
p. 577-579
|
artikel
|
| 18 |
Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial
|
Maher, Toby M
|
|
2018
|
6 |
8 |
p. 627-635
|
artikel
|
| 19 |
Small airways disease in mild and moderate chronic obstructive pulmonary disease: a cross-sectional study
|
Koo, Hyun-Kyoung
|
|
2018
|
6 |
8 |
p. 591-602
|
artikel
|
| 20 |
The anti-inflammatory properties of tiotropium
|
Benfante, Alida
|
|
2018
|
6 |
8 |
p. e37
|
artikel
|
| 21 |
The FLORA study: presenting a novel IPF trial design
|
Crestani, Bruno
|
|
2018
|
6 |
8 |
p. 572-573
|
artikel
|
| 22 |
The heterogeneity of chronic cough: a case for endotypes of cough hypersensitivity
|
Mazzone, Stuart B
|
|
2018
|
6 |
8 |
p. 636-646
|
artikel
|
| 23 |
The 1918 Influenza Pandemic: one hundred years of progress, but where now?
|
Barclay, Wendy
|
|
2018
|
6 |
8 |
p. 588-589
|
artikel
|
| 24 |
The perils posed by the US Environmental Protection Agency's transparency rule
|
Thurston, George D
|
|
2018
|
6 |
8 |
p. e40-e41
|
artikel
|
| 25 |
Towards genetic reclassification of idiopathic pulmonary fibrosis
|
Wain, Louise
|
|
2018
|
6 |
8 |
p. 569-570
|
artikel
|
| 26 |
Urgent need for pragmatic trial platforms in severe asthma
|
Pilette, Charles
|
|
2018
|
6 |
8 |
p. 581-583
|
artikel
|
Tijdschrift beschrijving